Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04852666 · ClinicalTrials.gov registry record
Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)
A clinical trial of Ulcerative Colitis and Crohn's Disease, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 465
- Enrollment target
- 2
- Study locations
NCT04852666 is a study of Ulcerative Colitis and Crohn's Disease that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 465 participants, below the 2,054-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04852666, a study of Ulcerative Colitis and Crohn's Disease, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 465 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess effectiveness of vedolizumab versus ustekinumab in patients with Crohn's disease and vedolizumab versus tofacitinib in patients with ulcerative colitis, after non-response to anti-tumor necrosis factor (TNF) medications, using data from two existing cohorts.
Conditions Studied
Study Locations (2)
New York
- Crohn's & Colitis Foundation - New York
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2022-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04852666
The ClinicalTrials.gov registry entry for NCT04852666 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 465 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,054-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (77% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 0 interventions.
NCT04852666 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04852666 about?
NCT04852666 is a clinical study titled "Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)". The purpose of this study is to assess effectiveness of vedolizumab versus ustekinumab in patients with Crohn's disease and vedolizumab versus tofacitinib in patients with ulcerative colitis, after non-response to anti-tumor necrosis factor (TNF) medications, using data from two existing cohorts.
What is the current status of trial NCT04852666?
This trial is currently completed. The enrollment target is 465 participants. The study started on 2019-07-25. Estimated completion is 2022-12-15.
What conditions does trial NCT04852666 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Crohn's Disease.
Who is sponsoring clinical trial NCT04852666?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04852666 being conducted?
This trial has 2 study locations across New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
RECRUITING
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
RECRUITING · NA
-
Registry and Biorepository for IBD in Central Texas
RECRUITING
-
Nicotinamide Riboside in Ulcerative Colitis
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.